{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:26:22Z","timestamp":1758817582633,"version":"3.41.2"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.515556","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T05:20:44Z","timestamp":1602739244000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma"],"prefix":"10.3389","volume":"11","author":[{"given":"Christophe","family":"Lallemand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Ferrando-Miguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Auer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Iglseder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Czech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anouk","family":"Gaber-Wagener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Di Pauli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Deisenhammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"Tovey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14791\/btrt.2017.5.1.1","article-title":"Bevacizumab in recurrent glioma: patterns of treatment failure.","volume":"5","author":"Li","year":"2017","journal-title":"Brain Tumor Res Treat."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.3892\/ol.2017.6251","article-title":"Bevacizumab as last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine.","volume":"14","author":"Wenger","year":"2017","journal-title":"Oncol Lett."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Vevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook.","volume":"86","author":"Garcia","year":"2017","journal-title":"Cancer Treat Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","article-title":"Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro.","volume":"7","author":"Wang","year":"2004","journal-title":"Angiogenesis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.4161\/mabs.19873","article-title":"Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter-gene assay.","volume":"4","author":"Parekh","year":"2012","journal-title":"MAbs."},{"key":"B6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jim.2011.08.022","article-title":"Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNF\u03b1 antagonists.","volume":"373","author":"Lallemand","year":"2011","journal-title":"J Immunol Methods."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/3908289","article-title":"A novel system for the quantification of the ADCC activity of therapeutic antibodies.","volume":"10","author":"Lallemand","year":"2017","journal-title":"J Immunol Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jpba.2016.03.042","article-title":"Development of a robust reporter-based assay for the bioactivity determination of anti-VEGF therapeutic antibodies.","volume":"125","author":"Wang","year":"2016","journal-title":"J Pharm Biomed Anal."},{"key":"B9","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"WHO classification of tumours of the central nervous system.","volume":"6","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"B10","first-page":"57","article-title":"Signals and genes induced by angiogenic growth factors in comparison to inflammatory cytokines in endothelial cells.","volume":"37","author":"Schweighofer","year":"2007","journal-title":"Clin Hemorheol Microcirc."},{"key":"B11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy.","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat Rev Drug Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11060-005-9097-6","article-title":"Mechanisms of angiogenesis in gliomas.","volume":"78","author":"Kargiotis","year":"2006","journal-title":"J Neurooncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrc2403","article-title":"VEGF-targeted therapy: mechanisms of anti-tumour activity.","volume":"8","author":"Ellis","year":"2008","journal-title":"Nat Rev Cancer."},{"key":"B14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1212\/WNL.0b013e318204a3af","article-title":"The paradoxical effect of bevacizumab in the therapy of malignant gliomas.","volume":"76","author":"Thompson","year":"2011","journal-title":"Neurology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/glia.21264","article-title":"The brain tumor microenvironment.","volume":"60","author":"Charles","year":"2012","journal-title":"Glia."},{"key":"B16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12974-019-1563-8","article-title":"Effects of VEGF blockade on the dynamics of the inflammatory landscape in glioblastoma-bearing mice.","volume":"16","author":"Souberan","year":"2019","journal-title":"J Neuroinflammation."},{"key":"B17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4161\/mabs.22775","article-title":"Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells.","volume":"5","author":"Marcucci","year":"2013","journal-title":"MAbs."},{"key":"B18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3109\/00365521.2010.536254","article-title":"Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn\u2019s disease.","volume":"46","author":"Steenholdt","year":"2011","journal-title":"Scand J Gastroenterol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus adiotherapy\/temozolomide for newly diagnosed glioblastoma.","volume":"370","author":"Chinot","year":"2014","journal-title":"N Eng J Med."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418790452","article-title":"Treatment of glioblastoma in adults.","volume":"11","author":"Wick","year":"2018","journal-title":"Ther Adv Neurol Disord."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.515556\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T05:20:48Z","timestamp":1602739248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.515556\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2020.515556"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.515556","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"article-number":"515556"}}